Indeed, a recent study showed that the presence of certain mutations (such as the TP53, KRAS/NRAS, and FLT3-ITD) had an adverse impact on the outcome of patients with de novo AML receiving less intensive chemotherapy [13]. This evidence concerns the gene FLT3 and acute myeloid leukemia.